Capital Fund Management S.A. Acquires 126,414 Shares of TransMedics Group, Inc. $TMDX

Capital Fund Management S.A. grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 100.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 252,294 shares of the company’s stock after buying an additional 126,414 shares during the period. Capital Fund Management S.A. owned 0.75% of TransMedics Group worth $16,974,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TMDX. Braidwell LP purchased a new position in shares of TransMedics Group during the 4th quarter valued at $57,493,000. Mackenzie Financial Corp lifted its position in shares of TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after buying an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after buying an additional 253,624 shares during the last quarter. Avidity Partners Management LP lifted its position in shares of TransMedics Group by 597.1% during the 4th quarter. Avidity Partners Management LP now owns 192,400 shares of the company’s stock valued at $11,996,000 after buying an additional 164,800 shares during the last quarter. Finally, Frontier Capital Management Co. LLC purchased a new position in shares of TransMedics Group during the 4th quarter valued at $9,415,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TMDX shares. Morgan Stanley upped their price target on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Tuesday, June 17th. Canaccord Genuity Group increased their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $121.88 on Thursday. The business’s 50-day moving average price is $122.60 and its two-hundred day moving average price is $100.65. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The stock has a market cap of $4.15 billion, a P/E ratio of 63.15 and a beta of 2.09. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm had revenue of $157.37 million for the quarter, compared to analysts’ expectations of $146.64 million. During the same quarter last year, the firm posted $0.35 EPS. The company’s revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of the firm’s stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director owned 12,134 shares of the company’s stock, valued at $1,503,159.92. This trade represents a 5.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 686 shares of the firm’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,418 shares of company stock valued at $818,833 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.